The Advanced Research Projects Agency for Health (ARPA-H) announced three promising osteoarthritis treatments that have regrown bone and cartilage in animal studies. Teams from Duke, the University of Colorado Boulder, and Columbia University are contractually obligated to begin clinical trials within 18 months. Their approaches range from targeted injections to a 3-D printed scaffold for full knee regeneration, aiming to cure rather than merely manage symptoms.

This push stems from ARPA-H's five-year, tens-of-millions investment targeting the 32 million Americans with osteoarthritis. The agency, modeled on DARPA, imposes strict commercialization terms: successful treatments must be affordable, costing no more than 25% of current standard care, and trials must include diverse populations, with over half of participants being women and inclusion of Native Americans.

For a market dominated by pain management drugs and joint replacements, a functional cure would be transformative. The $42 million awarded to Columbia's scaffold method exemplifies the scale of funding needed to bridge the gap from academic research to marketable therapy. If these regimens prove effective in humans, they could upend billions in annual arthritis care spending by offering a one-time regenerative solution.